- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01922895
Novel Therapies in Moderately Severe Acute Alcoholic Hepatitis (NTAH-Mod)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Aim 1: Evaluate the effects of probiotic supplements on improvement in MELD score and gut mucosal integrity in patients with MELD < 21. Patients will be randomized to receive daily probiotics for 6 months and standard of care treatment or placebo with standard care.
Aim 2: Document the natural history of moderately severe alcoholic hepatitis. Patients who decline randomization will be offered the option of inclusion in the study prospectively for data collection purposes and research study procedures.
Aim 3: Create a data and tissue biorepository. This biorepository will serve as a national resource for studies related to acute alcoholic hepatitis.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- University of Louisville
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic
-
-
Texas
-
Dallas, Texas, United States, 75390
- U Texas Southwestern Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ability to provide informed consent by subject or appropriate family member
- Age between 21-70 years
- Recent alcohol consumption > 50 g/d for > 6 months, continuing within two months before enrollment
- At least 2 of the following symptoms or signs of acute alcoholic hepatitis: Anorexia, nausea, RUQ pain, jaundice, leukocytosis, hepatomegaly AND
- Elevation of AST > 80 U/L, but < 500 U/L at the time of admission or within 3 days of baseline visit; AST > ALT and ALT < 200 U/L; total bilirubin > 3 mg/dL AND
- Liver biopsy showing alcoholic hepatitis (steatohepatitis) OR ultrasound of liver showing increased echogenicity OR CT scan showing decreased attenuation of liver compared to spleen OR MRI showing fatty liver (decreased signaling intensity on T1 weighted images). If the liver biopsy (done within 60 days of inclusion) confirms diagnosis of AAH then inclusion e will be waived.
- Model for End-Stage Liver Disease (MELD) <20
- Willingness to utilize two reliable forms of contraception (both males and females of childbearing potential) from screening through the first six weeks of study.
Exclusion Criteria:
- Hypotension with BP < 80/50 after volume repletion
- Pregnancy; incarceration; inability to provide consent or lack of appropriate family member
- Signs of systemic infection: Fever > 38o C and positive blood or ascites cultures on appropriate antibiotic therapy for > 3 days within 3 days of inclusion
- Acute gastrointestinal bleeding requiring > 2 units blood transfusion within the previous 4 days
- Undue risk from immunosuppression: Positive HBsAg; a positive skin PPD skin test or history of treatment for tuberculosis; history of any malignancy including hepatocellular carcinoma; known HIV infection
- Treatment with corticosteroids or other immunosuppressive medications including specific anti-TNF therapy (not including pentoxifylline), calcineurin inhibitors for > 3 days within the previous 3 months.
- Evidence of acute pancreatitis: CT evidence and/or amylase or lipase > 5 X upper limit of normal
- Serious cardiac, respiratory or neurologic disease or evidence of autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, Wilsons disease, hemochromatosis, secondary iron overload due to chronic hemolysis, alpha-1-antitrypsin deficiency
- Acute or chronic kidney injury with serum creatinine > 3.0 mg/dl
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo for Probiotic
Placebo capsule that matches the probiotic capsule in appearance will be given once daily for 180 days.
|
Capsule manufactured without active ingredients.
Other Names:
|
Active Comparator: Lactobacillus Rhamnosus GG
Dietary supplement capsule (Lactobacillus Rhamnosus GG) will be given once daily for 180 days.
|
Probiotic nutritional supplement; Lactobacillus Rhamnosus GG
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MELD Score
Time Frame: 30 days
|
Change in MELD scoring system for assessing the severity of chronic liver disease; MELD (Model of End Stage Liver Disease) scoring system for assessing the severity of chronic liver disease; calculated from serum bilirubin, serum creatinine, and the international normalized ratio for prothrombin time (INR) MELD = 3.8[Ln serum bilirubin (mg/dL)] + 11.2[Ln INR] + 9.6[Ln serum creatinine (mg/dL)] + 6.4.
MELD score range from 6-40 with higher scores indicating more severe liver disease and a worse outcome.
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MELD Score
Time Frame: 180 days
|
Change in MELD scoring system over 180 day study duration.
MELD (Model of End Stage Liver Disease) scoring system for assessing the severity of chronic liver disease; calculated from serum bilirubin, serum creatinine, and the international normalized ratio for prothrombin time (INR) MELD = 3.8[Ln serum bilirubin (mg/dL)] + 11.2[Ln INR] + 9.6[Ln serum creatinine (mg/dL)] + 6.4.
MELD score range from 6-40 with higher scores indicating more severe liver disease and a worse outcome.
|
180 days
|
MELD Score
Time Frame: 90 days
|
Change in MELD scoring system at 90 days study duration.
MELD (Model of End Stage Liver Disease) scoring system for assessing the severity of chronic liver disease; calculated from serum bilirubin, serum creatinine, and the international normalized ratio for prothrombin time (INR) MELD = 3.8[Ln serum bilirubin (mg/dL)] + 11.2[Ln INR] + 9.6[Ln serum creatinine (mg/dL)] + 6.4.
MELD score range from 6-40 with higher scores indicating more severe liver disease and a worse outcome.
|
90 days
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Mack C Mitchell, M.D., U Texas Southwestern Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Chemically-Induced Disorders
- Digestive System Diseases
- Alcohol-Related Disorders
- Substance-Related Disorders
- RNA Virus Infections
- Virus Diseases
- Infections
- Liver Diseases
- Hepatitis, Viral, Human
- Enterovirus Infections
- Picornaviridae Infections
- Liver Diseases, Alcoholic
- Alcohol-Induced Disorders
- Hepatitis
- Hepatitis A
- Hepatitis, Alcoholic
Other Study ID Numbers
- STU 092012-012
- U01AA021893-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Alcoholic Hepatitis
-
Vital Therapies, Inc.CompletedAcute Alcoholic HepatitisUnited States, Spain, Australia, United Kingdom
-
Vital Therapies, Inc.TerminatedAcute Alcoholic HepatitisUnited States, Spain, United Kingdom, Germany, Austria, Ireland
-
Conatus Pharmaceuticals Inc.TerminatedLiver Cirrhosis | Acute on Chronic Hepatic Failure | Acute Liver Failure | Acute Alcoholic HepatitisUnited States, United Kingdom
-
Methodist Health SystemRecruiting
-
Vital Therapies, Inc.TerminatedSevere Acute Alcoholic HepatitisUnited States, Spain, United Kingdom, Germany
-
MedRegen LLCNot yet recruitingAlcoholic Hepatitis | Acute Alcoholic Hepatitis
-
Mack MitchellNational Institute on Alcohol Abuse and Alcoholism (NIAAA); The Cleveland Clinic and other collaboratorsCompletedAcute Alcoholic HepatitisUnited States
-
Centre Hospitalier Universitaire, AmiensCH MontdidierRecruitingCorticosteroids | Intestinal Microbiota | Alcohol | Severe Acute Alcoholic HepatitisFrance
-
AfimmuneTerminatedSevere Acute Decompensated Alcoholic HepatitisUnited States, Georgia
-
CytoSorbents Europe GmbHWithdrawnAlcoholic Hepatitis | Acute on Chronic Liver FailureGermany
Clinical Trials on Placebo for Probiotic
-
Shandong UniversityUnknownGastrointestinal Neoplasms | Colorectal Cancer | Malnutrition | Effects of Chemotherapy | Tumor ImmunityChina
-
IBSS Biomed S.A.Ministry of Science and Higher Education, PolandCompletedNecrotizing Enterocolitis | Infant, Very Low Birth Weight | Late Onset Neonatal Sepsis
-
University Hospital TuebingenCompleted
-
Hamilton Health Sciences CorporationRecruitingClostridium Difficile Diarrhea | Clostridium Difficile ColonizationCanada
-
Centros de Investigación de Nutrición y SaludNutribioticaCompletedFunctional ConstipationSpain
-
Universiti Kebangsaan Malaysia Medical CentreUnknownHypertension | Obesity | Type 2 Diabetes Mellitus | HyperlipidemiaMalaysia
-
Maastricht University Medical CenterCompleted
-
National Taiwan University HospitalNot yet recruitingIrritable Bowel Syndrome | Metabolic Syndrome | Microbial Colonization
-
Fundació Sant Joan de DéuCompleted
-
University of LeedsUnknown